Τρίτη 20 Οκτωβρίου 2020

 

Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation
Future Oncology, Ahead of Print. (Source: Future Oncology)
Future Oncology
1w
A theoretical model of financial burden after cancer diagnosis
Future Oncology, Ahead of Print. (Source: Future Oncology)
Future Oncology
1w
Demographic factors associated with missed follow-up among solid tumor patients treated at a large multi-site academic institution
Future Oncology, Ahead of Print. (Source: Future Oncology)
Future Oncology
1w
Role of indoleamine 2,3-dioxygenase in acute myeloid leukemia
Future Oncology, Ahead of Print. (Source: Future Oncology)
Future Oncology
1w
Clinical applications of circulating tumor DNA in monitoring breast cancer drug resistance
Future Oncology, Ahead of Print. (Source: Future Oncology)
Future Oncology
1w
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations
Future Oncology, Ahead of Print. (Source: Future Oncology)
Future Oncology
1w
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma
Future Oncology, Ahead of Print. (Source: Future Oncology)
Future Oncology
1w
Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in the Japanese population
Future Oncology, Ahead of Print. (Source: Future Oncology)
Future Oncology
1w
Physician treatment of metastatic triple-negative breast cancer in the immuno-oncology era: a discrete choice experiment
Future Oncology, Ahead of Print. (Source: Future Oncology)
Future Oncology
1w
Polatuzumab vedotin, an anti-CD79b antibody –drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma
Future Oncology, Ahead of Print. (Source: Future Oncology)
Future Oncology
1w
REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer
Future Oncology, Ahead of Print. (Source: Future Oncology)
Future Oncology
1w
USP44 hypermethylation promotes cell proliferation and metastasis in breast cancer
Future Oncology, Ahead of Print. (Source: Future Oncology)
Future Oncology
1w
Interaction of HULC polymorphisms with Helicobacter pylori infection plays a strong role for the prediction of gastric cancer risk
Future Oncology,Volume 16, Issue 26, Page 1997-2006, September 2020. (Source: Future Oncology)
Future Oncology
1w
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer
Future Oncology, Ahead of Print. (Source: Future Oncology)
Future Oncology
1w
Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab
Future Oncology, Ahead of Print. (Source: Future Oncology)
Future Oncology
1w
Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data
Future Oncology, Ahead of Print. (Source: Future Oncology)
Future Oncology
1w
RNA in cancer
Nature Reviews Cancer, Published online: 20 October 2020; doi:10.1038/s41568-020-00306-0This Review discusses how altered processing or activity of coding and non-coding RNAs contributes to cancer, introducing the regulation of gene expression by coding and non-coding RNA and discussing both established and emerging roles for RNAs in cancer.
Nature Reviews Cancer - Issue - nature.com science feeds
11h
RNA in cancer
Nature Reviews Cancer - Issue - nature.com science feeds
13h
Targeted Therapy: What Are Invasion and Metastasis in cancer?
Title: Targeted Therapy: What Are Invasion and Metastasis in cancer?Category: MedicationsCreated: 10/19/2020 12:00:00 AMLast Editorial Review: 10/19/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
11h
Insured Patients Are Getting Surprise Bills After Colonoscopies
Title: Insured Patients Are Getting Surprise Bills After ColonoscopiesCategory: Health NewsCreated: 10/16/2020 12:00:00 AMLast Editorial Review: 10/19/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
11h
More Prostate Cancers Are Being Diagnosed at a Later Stage
Title: More Prostate Cancers Are Being Diagnosed at a Later StageCategory: Health NewsCreated: 10/16/2020 12:00:00 AMLast Editorial Review: 10/19/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
11h
Targeted Therapy: What Is Replicative Immortality in Cancer?
Title: Targeted Therapy: What Is Replicative Immortality in Cancer?Category: MedicationsCreated: 10/19/2020 12:00:00 AMLast Editorial Review: 10/19/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
11h
Many Male Breast Cancers Diagnosed Late, and Delays Can Be Lethal
Title: Many Male Breast Cancers Diagnosed Late, and Delays Can Be LethalCategory: Health NewsCreated: 10/15/2020 12:00:00 AMLast Editorial Review: 10/16/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
3d
Unituxin (dinutuximab)
Title: Unituxin (dinutuximab)Category: MedicationsCreated: 10/15/2020 12:00:00 AMLast Editorial Review: 10/15/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
3d
Early Signs and Symptoms of Penis Cancer
Title: Early Signs and Symptoms of Penis CancerCategory: Diseases and ConditionsCreated: 10/15/2020 12:00:00 AMLast Editorial Review: 10/15/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
3d
What Is a Grade 4 Tumor?
Title: What Is a Grade 4 Tumor?Category: Diseases and ConditionsCreated: 10/15/2020 12:00:00 AMLast Editorial Review: 10/15/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
3d
Erleada (apalutamide)
Title: Erleada (apalutamide)Category: MedicationsCreated: 10/14/2020 12:00:00 AMLast Editorial Review: 10/14/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
3d
Onureg (azacitidine)
Title: Onureg (azacitidine)Category: MedicationsCreated: 10/14/2020 12:00:00 AMLast Editorial Review: 10/14/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
3d
Kadcyla (ado-trastuzumab emtansine)
Title: Kadcyla (ado-trastuzumab emtansine)Category: MedicationsCreated: 10/14/2020 12:00:00 AMLast Editorial Review: 10/14/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
4d
Is Kidney Cancer Curable?
Title: Is Kidney Cancer Curable?Category: Diseases and ConditionsCreated: 10/14/2020 12:00:00 AMLast Editorial Review: 10/14/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
4d
What Are the Warning Signs of Liver Cancer?
Title: What Are the Warning Signs of Liver Cancer?Category: Diseases and ConditionsCreated: 10/14/2020 12:00:00 AMLast Editorial Review: 10/14/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
4d
Cancer Takes Heavy Toll on Women's Work and Finances: Study
Title: Cancer Takes Heavy Toll on Women's Work and Finances: StudyCategory: Health NewsCreated: 10/12/2020 12:00:00 AMLast Editorial Review: 10/13/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
5d
Keytruda (pembrolizumab)
Title: Keytruda (pembrolizumab)Category: MedicationsCreated: 10/13/2020 12:00:00 AMLast Editorial Review: 10/13/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
5d
Subsys (fentanyl)
Title: Subsys (fentanyl)Category: MedicationsCreated: 10/13/2020 12:00:00 AMLast Editorial Review: 10/13/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
5d
The Early Stages of Mouth Cancer
Title: The Early Stages of Mouth CancerCategory: Diseases and ConditionsCreated: 10/12/2020 12:00:00 AMLast Editorial Review: 10/12/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
The First Sign of Testicular Cancer?
Title: The First Sign of Testicular Cancer?Category: Diseases and ConditionsCreated: 10/12/2020 12:00:00 AMLast Editorial Review: 10/12/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Detectnet (copper Cu 64 dotatate)
Title: Detectnet (copper Cu 64 dotatate)Category: MedicationsCreated: 10/9/2020 12:00:00 AMLast Editorial Review: 10/9/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Targeted Therapy: What Is Oncogenic Addiction in Cancer Cells?
Title: Targeted Therapy: What Is Oncogenic Addiction in Cancer Cells?Category: MedicationsCreated: 10/9/2020 12:00:00 AMLast Editorial Review: 10/9/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
What Are the Early Warning Signs of Stomach Cancer?
Title: What Are the Early Warning Signs of Stomach Cancer?Category: Diseases and ConditionsCreated: 10/9/2020 12:00:00 AMLast Editorial Review: 10/9/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
What Foods Increase the Risk of Cancer?
Title: What Foods Increase the Risk of Cancer?Category: Diseases and ConditionsCreated: 10/9/2020 12:00:00 AMLast Editorial Review: 10/9/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Targeted Therapy: What Are The 10 Hallmarks of Cancer?
Title: Targeted Therapy: What Are The 10 Hallmarks of Cancer?Category: MedicationsCreated: 10/9/2020 12:00:00 AMLast Editorial Review: 10/9/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
DNA Analysis Might Reveal Melanoma Risk
Title: DNA Analysis Might Reveal Melanoma RiskCategory: Health NewsCreated: 10/8/2020 12:00:00 AMLast Editorial Review: 10/9/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Stivarga (regorafenib)
Title: Stivarga (regorafenib)Category: MedicationsCreated: 10/8/2020 12:00:00 AMLast Editorial Review: 10/8/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Ninlaro (ixazomib)
Title: Ninlaro (ixazomib)Category: MedicationsCreated: 10/8/2020 12:00:00 AMLast Editorial Review: 10/8/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
What Type of Cancer Makes You Very Tired?
Title: What Type of Cancer Makes You Very Tired?Category: Diseases and ConditionsCreated: 10/7/2020 12:00:00 AMLast Editorial Review: 10/7/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Radiation Plus Surgery May Be Best Against an Early Form of Breast Cancer
Title: Radiation Plus Surgery May Be Best Against an Early Form of Breast CancerCategory: Health NewsCreated: 10/5/2020 12:00:00 AMLast Editorial Review: 10/6/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
At What Stage of Cancer is Chemotherapy Used?
Title: At What Stage of Cancer is Chemotherapy Used?Category: Diseases and ConditionsCreated: 10/6/2020 12:00:00 AMLast Editorial Review: 10/6/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Is Gallbladder Cancer Aggressive?
Title: Is Gallbladder Cancer Aggressive?Category: Diseases and ConditionsCreated: 10/6/2020 12:00:00 AMLast Editorial Review: 10/6/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Drug Combo Approved for First-Line Treatment of Mesothelioma
Title: Drug Combo Approved for First-Line Treatment of MesotheliomaCategory: Health NewsCreated: 10/5/2020 12:00:00 AMLast Editorial Review: 10/6/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Gavreto (pralsetinib)
Title: Gavreto (pralsetinib)Category: MedicationsCreated: 10/2/2020 12:00:00 AMLast Editorial Review: 10/2/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Yonsa (abiraterone acetate)
Title: Yonsa (abiraterone acetate)Category: MedicationsCreated: 10/2/2020 12:00:00 AMLast Editorial Review: 10/2/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Immunotherapy Drug Boosts Survival for Lung Cancer Patients
Title: Immunotherapy Drug Boosts Survival for Lung Cancer PatientsCategory: Health NewsCreated: 10/1/2020 12:00:00 AMLast Editorial Review: 10/2/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
HPV Vaccine Proves Its Mettle Against Cervical Cancer
Title: HPV Vaccine Proves Its Mettle Against Cervical CancerCategory: Health NewsCreated: 9/30/2020 12:00:00 AMLast Editorial Review: 10/1/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Foods, Medicines That Can Lower Colon Cancer Risk
Title: Foods, Medicines That Can Lower Colon Cancer RiskCategory: Health NewsCreated: 9/30/2020 12:00:00 AMLast Editorial Review: 10/1/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Is Uterus Cancer Fatal?
Title: Is Uterus Cancer Fatal?Category: Diseases and ConditionsCreated: 9/30/2020 12:00:00 AMLast Editorial Review: 9/30/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Breast Cancer Treatment Comes Later, Lasts Longer for Black Women
Title: Breast Cancer Treatment Comes Later, Lasts Longer for Black WomenCategory: Health NewsCreated: 9/25/2020 12:00:00 AMLast Editorial Review: 9/28/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Can Lymphoma Be Completely Cured?
Title: Can Lymphoma Be Completely Cured?Category: Diseases and ConditionsCreated: 9/24/2020 12:00:00 AMLast Editorial Review: 9/24/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Smoking Reduces Survival Odds After Bladder Cancer Surgery
Title: Smoking Reduces Survival Odds After Bladder Cancer SurgeryCategory: Health NewsCreated: 9/23/2020 12:00:00 AMLast Editorial Review: 9/24/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Certain Cancer Treatments May Heighten Danger From COVID-19
Title: Certain Cancer Treatments May Heighten Danger From COVID-19Category: Health NewsCreated: 9/22/2020 12:00:00 AMLast Editorial Review: 9/23/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Is an Early Form of Breast Cancer More Dangerous Than Thought?
Title: Is an Early Form of Breast Cancer More Dangerous Than Thought?Category: Health NewsCreated: 9/22/2020 12:00:00 AMLast Editorial Review: 9/22/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
 
Immunotherapy Drug Boosts Survival With Bladder Cancer
Title: Immunotherapy Drug Boosts Survival With Bladder CancerCategory: Health NewsCreated: 9/21/2020 12:00:00 AMLast Editorial Review: 9/22/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Many High-Risk Patients Don't Know They Need Follow-Up Colonoscopy
Title: Many High-Risk Patients Don't Know They Need Follow-Up ColonoscopyCategory: Health NewsCreated: 9/18/2020 12:00:00 AMLast Editorial Review: 9/21/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Supreme Court Justice Ruth Bader Ginsburg Dies at 87
Title: Supreme Court Justice Ruth Bader Ginsburg Dies at 87Category: Health NewsCreated: 9/19/2020 12:00:00 AMLast Editorial Review: 9/21/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Coffee Can Slow Colon Cancer
Title: Coffee Can Slow Colon CancerCategory: Health NewsCreated: 9/17/2020 12:00:00 AMLast Editorial Review: 9/18/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Almost 90,000 Young American Adults Will Get Cancer This Year: Report
Title: Almost 90,000 Young American Adults Will Get Cancer This Year: ReportCategory: Health NewsCreated: 9/18/2020 12:00:00 AMLast Editorial Review: 9/18/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Mother and Son Draw Hope, Healing From Shared Cancer Treatment
Title: Mother and Son Draw Hope, Healing From Shared Cancer TreatmentCategory: Health NewsCreated: 9/17/2020 12:00:00 AMLast Editorial Review: 9/18/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Your Biological Sex Affects Genes for Cancer, Body Fat, Birth Weight
Title: Your Biological Sex Affects Genes for Cancer, Body Fat, Birth WeightCategory: Health NewsCreated: 9/15/2020 12:00:00 AMLast Editorial Review: 9/16/2020 12:00:00 AM (Source: MedicineNet Cancer General)
MedicineNet Cancer General
1w
Long-term follow-up 3  years after a randomized rehabilitation study among radiated prostate cancer survivors
ConclusionThe short-term rehabilitation was beneficial but of limited benefit in the long term for all patients. A significant and clinically relevant effect was found in irradiated prostate cancer patients with moderate-severe urinary problems at baseline. In both groups, pelvic floor strength was weakened during follow-up.Impact for cancer survivorsPrior research showed patients benefit from early rehabilitation. Identification of patients with moderate-severe urinary problems followed by a focused...
Journal of Cancer Survivorship
12h
Body composition and its association with fatigue in the first 2  years after colorectal cancer diagnosis
ConclusionHaving more SAT was associated with more fatigue at diagnosis, while low levels of SMR were associated with more fatigue at 6  months post-diagnosis.Implications for Cancer SurvivorsOur results suggest that it may be interesting to investigate whether interventions that aim to increase SMR around the time of diagnosis may help to lower fatigue. However, more knowledge is needed to understand the mechanisms behind the association of SMR with fatigue. (Source: Journal of Cancer Survivorship)
Journal of Cancer Survivorship
4d
Caregiving burden among informal caregivers of African American cancer survivors
ConclusionsCaregivers for African American cancer survivors provide many hours of care, yet most describe their CGB as low. Although ADL assistance is often available through the healthcare system, assistance with IADLs presents an opportunity to lessen the burden for these caregivers and their care recipients.Implications for Cancer SurvivorsAfrican American cancer survivors receive much care from informal family caregivers, who assist with multiple ADLs and IADLs. Formal IADL assistance programs,...
Journal of Cancer Survivorship
4d
Rural breast cancer survivors are able to maintain diet quality improvements during a weight loss maintenance intervention
ConclusionsOverall DQ improvements made during a weight loss intervention for rural breast cancer survivors were sustained during a weight loss maintenance intervention; this intervention was effective in helping low regainers maintain healthier scores in fruit, red meat, and sugar-sweetened beverage components.Implications for Cancer SurvivorsMaintaining higher DQ may help breast cancer survivors maintain weight loss, thereby reducing risk of breast cancer recurrence and premature death from comorbidities....
Journal of Cancer Survivorship
5d
Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners
ConclusionsMen with prostate cancer have a higher risk of receiving antidepressant medication than cancer-free men. Clinical characteristics can help clinicians in identifying patients at a high risk of depression or anxiety.Implications for Cancer SurvivorsMen with prostate cancer who experience symptoms of depression or anxiety should seek professional help early on. Patient education could aid in raising awareness and reducing the stigma associated with mental disorders. (Source: Journal of Cancer...
Journal of Cancer Survivorship
1w
Integrated histological and molecular analyses of rebiopsy samples at osimertinib progression improves post-progression survivals: a single-center retrospective study
Osimertinib is the standard of care for patients with advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) who develop EGFR T790M-mediated failure from first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) [1 –4]. Approximately 70% of EGFR T790M-positive patients respond to osimertinib; however, resistance eventually develops after a median response of 10 months due to various EGFR-dependent and -independent mechanisms [3–7]. Current National Comprehensive...
Lung Cancer
12h
Oncolytic herpesvirus therapy for mesothelioma – A Phase I/IIa trial of intrapleural administration of HSV1716
Worldwide, 30,443 cases of malignant pleural mesothelioma (MPM) are diagnosed annually [1]. Incidence has plateaued in the USA and Western Europe but is still rising in Eastern Europe and Asia, reflecting continued asbestos use. The prognosis for MPM is poor. Many patients experience severe chest pain and breathlessness and most die within a year of diagnosis. (Source: Lung Cancer)
Lung Cancer
12h
Corrigendum to “73 - Five years of stereotactic radiotherapy for early lung cancer: Biopsy rates, outcomes and implications” [Lung Cancer, 139, 1, (January 2020) Page S31]
The authors regret that four authors were erroneously omitted from the authorship list of this abstract. The correct authorship list is presented above. (Source: Lung Cancer)
Lung Cancer
1d
Editorial Board
(Source: Lung Cancer)
Lung Cancer
4d
Contents
(Source: Lung Cancer)
Lung Cancer
4d
Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs)
Neuroendocrine tumours (NETs) are a heterogeneous group of hormone-secreting neoplasms that arise from the diffuse endocrine system [1]. They are relatively rare and comprise ∼0.9 % of all tumours, with an incidence of seven per 100,000 per year [2,3]. The majority of NETs (61 %) derive from gastroenteropancreatic tissues; 27 % are bronchial in origin [2]. Bronchial NETs arise from pulmonary neuroendocrine cells [4]. They are categorised by the World Health Organisatio n (WHO) into four morphological...
Lung Cancer
4d
Corrigendum to “Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma” [Lung Cancer 145 (2020) 158–166]
The authors regret that the in-text citations relating to a “Supplementary Figure” in Section 3.2 and Section 4 of the above article are incorrect. The correct in-text citations should lead readers to Fig. 5c. (Source: Lung Cancer)
Lung Cancer
1w
The potential of 18F-FDG PET/CT in predicting PDL1 expression status in pulmonary lesions of untreated stage IIIB-IV non-small-cell lung cancer
Lung cancer is the most lethal malignancy worldwide, whereas non-small-cell lung cancer (NSCLC) accounts for 83% of lung cancer cases[1,2]. More than two-thirds of lung cancers are diagnosed at a locally advanced or metastatic stage, and modern immunotherapy is essential to improve patient outcomes in such cases[2,3]. Programmed cell death-1 (PD1)/programmed cell death ligand-1 (PDL1) inhibitors (e.g., pembrolizumab and atezolizumab) are the main drugs used for lung cancer immunotherapy, and the...
Lung Cancer
1w
Antitumor Activity of Lurbinectedin in Second-line Small Cell Lung Cancer Patients Who Are Candidates for Re-challenge with the First-line Treatment
Standard first-line chemotherapy for patients with small cell lung cancer (SCLC) consists of a platinum salt (carboplatin or cisplatin) in combination with etoposide [1,2]. Recently, atezolizumab [3] or durvalumab [4] plus carboplatin/etoposide showed improved survival compared to chemotherapy alone, and both have been approved by the US FDA as first-line therapy. However, therapeutic options are limited once patients with SCLC have relapsed disease. The National Comprehensive Cancer Network (NCCN)...
Lung Cancer
1w
Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II –IIIA (N1–N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study
For patients with stage II –IIIA non-small-cell lung cancer (NSCLC), the current standard-of-care modality is surgery followed by adjuvant cisplatin-based chemotherapy [1,2]. However, the 5-year survival rate is only 19 %–46 % [3], and high toxicity and low compliance with this combined modality approach makes its benefit -risk ratio more unfavorable. To address this unmet medical need, the ADJUVANT study was conducted to test whether the epidermal growth factor receptor-tyrosine kinase inhibitor...
Lung Cancer
1w
Factors Associated with Treatment Receipt and Overall Survival for Patients with Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung: A National Cancer Database Analysis
Lung neuroendocrine tumors are comprised of several subtypes of pulmonary malignancies including large cell neuroendocrine carcinoma (LCNEC), small-cell lung cancer (SCLC), typical carcinoids (TC), and atypical carcinoids (AC). Approximately 20% of all pulmonary malignancies are neuroendocrine in origin with LCNEC representing only approximately 2-3% of all lung cancers [1]. LCNEC and SCLC exhibit similar clinical features such as increased incidence in older males with a history of smoking, high...
Lung Cancer
1w
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)
Lung cancer is the leading cause of cancer death worldwide [1,2]. Targeting oncogenic driver mutations has transformed the care of cancer patients. Targeted agents currently approved for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC) patients include the first-generation reversible EGFR tyrosine-kinase inhibitors (TKIs), erlotinib and gefitinib, the second-generation irreversible EGFR TKIs, such as afatinib and dacomitinib, and the recently approved third-generation EGFR TKI, osimertinib...
Lung Cancer
1w
Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients
Malignant pleural mesothelioma (MPM) is a rare and extremely aggressive tumor responsible for over 27,000 deaths per year worldwide ([1,2]). First-line therapeutic approaches include surgery, radiations, and chemotherapy ([2,3]). Regrettably, MPMs are refractory to standard treatments, as demonstrated by the short median overall survival rate (9.5 months) ([3]). A new possible treatment opportunity for MPM patients stems from the introduction of a new class of immunotherapeutic drugs, known as immune...
Lung Cancer
1w
A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma
Primary tumour volume (T-volume) is a critical determinant of survival and a key component of Tumor, Node, Metastases (TNM) cancer staging. Simple surrogates of tumour volume, such as unidimensional measurements perform well in many cancers (e.g. Lung Cancer) [1], but Malignant Pleural Mesothelioma (MPM) forms a complex, rind-like primary tumor that is difficult to accurately measure. As a result, current T-staging describes only the extent of invasion into adjacent tissues and does not account for...
Lung Cancer
1w
MET-mutant cancer and immune checkpoint inhibitors: A large database analysis
In the article by Yang et al. [1], it was identified that lung cancer patients with MET exon 14 (METex14) alterations achieve longer progression-free survival on crizotinib than on chemotherapy. Unfortunately, there were no significant differences in overall survival between these two subgroups. In addition, the prevalence of METex14 alterations was only 1.1 % in Chinese lung cancer patients, and the therapeutic strategies for cancers with MET non-ex14 mutations, such as MET kinase domain or semaphorin...
Lung Cancer
1w
Analysis of angiogenic and stromal biomarkers in a large malignant mesothelioma cohort
Angiogenesis is a complex process involving the interaction between tumour cells, growth factors and cells within the tumour microenvironment (TME). The purported primary stimulus for angiogenesis in the TME is the hypoxia-driven activation of hypoxia-inducible factor-1 α, and the subsequent activation of VEGF, along with many other growth factors including platelet derived growth factors, endothelial growth factors and fibroblast growth factor.1–3 The interaction between these cells within the TME...
Lung Cancer
1w
Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis
Discovery of somatic mutations in the epidermal growth factor receptor (EGFR) and EGFR tyrosine kinase inhibitors (TKIs) has improved the survival of patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. However, lung tumors inevitably acquire resistance to EGFR-TKIs within 18 months [1 –3]. To develop potent alternative treatment strategies, EGFR-TKI-resistant tumors have been widely examined, and multiple resistance mechanisms, such as EGFR T790 M mutation, MET amplification,...
Lung Cancer
1w
Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib
Lung cancer, which consists of approximately 80% non-small cell lung cancer (NSCLC) and 20% small cell lung cancer, has remained leading cause of all cancer deaths worldwide. The advances in targeted therapies against several driver mutations such as EGFR and ALK and immunotherapy have drastically improved 5-years survival of NSCLC patients (up to 19%) for the past decade in the USA [1]. Treatment of NSCLCs with activating EGFR mutations (e.g., 19del and L858R) using EGFR-tyrosine kinase inhibitors...
Lung Cancer
1w
Impact of histological components on selecting limited lymphadenectomy for lung adenocarcinoma ≤ 2 cm
In lung cancer surgery, systematic mediastinal lymphadenectomy (SML) is the golden standard for the histological staging of lymph node spread [1]. But thorough nodal dissection may prolong operative time and drainage, and increase damage of adjacent mediastinal structures [2]. Therefore, many surgeons avoid SML, and instead perform limited mediastinal lymphadenectomy (LML, less invasive lymphadenectomy or even omitting N2 nodal dissection) [3]. However, incomplete mediastinal nodal dissection may...
Lung Cancer
1w
Response to Osimertinib in a NSCLC Patient Harboring EGFR V843I Germ-Line Mutation
Epidermal growth factor receptor (EGFR) mutations have become a routine genetic test in the molecular diagnosis of non-small cell lung cancer (NSCLC). Although rarely, the germ-line EGFR variants, including R776X, T790  M, V843I and P848 L, have been reported (less than 0.1%) 1,2. Notably, EGFR V843I is associated with resistance to platinum-based chemotherapy and 1st-generation tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib 3,4. Matsushima et al. demonstrated that EGFR V843I mutation...
Lung Cancer
1w
Sarcopenia as independent risk factor of postpneumonectomy respiratory failure, ARDS and mortality
(Source: Lung Cancer)
Lung Cancer
1w
Value of interim 18F-FDG PET/CT for predicting progression-free survival in Stage ⅢB/IV EGFR-mutant non–small-cell lung cancer patients with EGFR-TKI therapy
Non –small-cell lung cancer (NSCLC) is the leading cause of cancer death worldwide 1. The incidence and mortality of lung cancer are among the highest of all cancers 2. NSCLC sometimes presents without any symptoms, and therefore, in the majority of patients, the disease is in an advanced stage when t he patients are admitted to the hospital 3. For advanced-stage NSCLC, the use of combined platinum-based chemotherapy has its limitations, and the efficacy of this treatment is poor. Researchers have...
Lung Cancer
1w
A rare EGFR mutation L747P conferred therapeutic efficacy to both ge fitinib and osimertinib: a case report
In the past decades the epidermal growth factor receptor gene (EGFR) has become an important therapeutic target for the treatment of non-small-cell lung cancer (NSCLC), particularly in patients with lung adenocarcinoma. The development of EGFR tyrosine kinase inhibitors (EGFR-TKIs) has revolutionized the treatment of NSCLC in patients harboring EGFR mutations [1,2]. Although more than half of Chinese patients with advanced NSCLC are found to have EGFR mutations, EGFR-TKIs are primarily administered...
Lung Cancer
1w
Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer
Anaplastic lymphoma kinase (ALK) gene rearrangement counts for approximately 5 % –7 % of non-small cell lung cancer (NSCLC) [1]. This kind of fusion represents a distinct mechanism of driver mutation in NSCLC. More than 19 different fusion partners have been identified in cancer patients [2]. The fusion of echinoderm microtubule-associated protein like 4 (EML4) and ALK is the most common fusion pattern, which occurred in at least 80 % ALK positive lung cancers [3,4]. (Source: Lung Cancer)
Lung Cancer
1w
Identification of a novel gene expression signature associated with overall survival in patients with lung adenocarcinoma: A comprehensive analysis based on TCGA and GEO databases
Lung cancer is the second most common cancer and the leading cause of cancer death in both men and women [1]. Low lung cancer survival rates reflect the large proportion of patients diagnosed with metastatic disease, for which the 5-year relative survival rate is 5 %, far lower than a 57 % survival rate in patients with localized stage disease [1]. Non-small cell lung cancer (NSCLC) accounts for nearly 90 % of lung cancer cases, and lung adenocarcinoma (LUAD) represents the most common histologic...
Lung Cancer
1w
Lung Cancer Screening Intervals Based on Cancer Risk
Annual screening for lung cancer using low-dose CT (LDCT) has been implemented in the United States since 2015 [1] based primarily on the National Lung Screening Trial (NLST) [2] and cohort studies [3]. The initial decision to perform screening annually was based on typical volume doubling times (VDTs) of lung cancers and modeling results [4,5], but some suggest it is not based on biologic evidence [6]. Changing the screening interval to two years or even longer intervals has been suggested [6 –15]...
Lung Cancer
1w
Application of clinical trial inclusion criteria to clinical practice patients to quantify the burden of CNS metastases on health-related quality of life and healthcare resource use in patients with NSCLC
Lung cancer remains the most common cancer worldwide and the most frequent cause of cancer death [1], with non-small-cell lung cancer (NSCLC) accounting for 85 –90 % of all cases [2]. Around 70 % of patients with NSCLC present with advanced disease at initial diagnosis, for which there are limited successful treatment options. A median overall survival (OS) of 12.3–22.0 months has been reported in patients with advanced NSCLC [3–5]. (Source: Lung Cancer)
Lung Cancer
1w
Editorial Board
(Source: Lung Cancer)
Lung Cancer
1w
Contents
(Source: Lung Cancer)
Lung Cancer
1w

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου